^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    cobas® EZH2 Mutation Test

    Company:
    Roche
    Type:
    FDA Approved
    Related tests:
    4ms
    Performance of the cobas EZH2 mutation test on clinical samples from non-Hodgkin lymphoma patients. (PubMed, PLoS One)
    cobas EZH2 Test data demonstrated that the test is reliable and will perform well in a commercial customer environment.
    Journal
    |
    EZH2 mutation
    |
    cobas® EZH2 Mutation Test
    3years
    [VIRTUAL] Phase 2 study of tazemetostat in Japanese patients with relapsed or refractory EZH2 mutation-positive B-cell Non-Hodgkin’s Lymphoma (AACR 2021)
    The ORR in subjects who received prior treatment with bendamustine, rituximab, and CHOP was 87.5%, 76.9%, and 76.9%, respectively. Tazemetostat at a dose of 800 mg BID showed encouraging efficacy in patients with relapsed or refractory EZH2 mutation-positive FL with an acceptable safety profile in the overall population. Thus, tazemetostat may be a potential option for the treatment of relapsed or refractory EZH2 mutation-positive FL.
    P2 data • Clinical
    |
    EZH2 mutation • EZH2 positive
    |
    cobas® EZH2 Mutation Test
    |
    Rituxan (rituximab) • Tazverik (tazemetostat) • bendamustine